GOSS - Gossamer Bio's GB004 shows positive action in early-stage ulcerative colitis study

Gossamer Bio (GOSS) has announced new data from GB004's Phase 1b study, on the reduction of fecal calprotectin, an inflammatory biomarker in inflammatory bowel disease ((IBD)), and the resolution of rectal bleeding, which is considered to be an objective measure of disease activity. Data were presented at UEGW Virtual 2020.GB004 is an oral, gut-targeted HIF-1? stabilizer, designed to promote mucosal healing and resolve local inflammationKey exploratory outcomes in GB004 arm compared to placebo include - Mucosal Healing 17% (4/23) and 0% (0/11); Histologic Remission 43% (10/23) and 18% (2/11); resolution of Rectal Bleeding 57% (12/21) and 36% (4/11); and reduction from Baseline in Fecal Calprotectin 38% (n=21) and 7% (n=11).Additionally, in a preclinical human monolayer assay, GB004 demonstrated superior protection of barrier integrity compared to Pfizer's tofacitinib, a pan-JAK inhibitor approved for moderate-to-severe ulcerative colitis ((UC)).Gossamer has initiated patient screening for Phase 2 UC study in patients who have received treatment with 5-aminosalicylate (5-ASA) therapy.

For further details see:

Gossamer Bio's GB004 shows positive action in early-stage ulcerative colitis study